Literature DB >> 22333973

miRNAs versus oncogenes: the power of social networking.

Marcos Malumbres1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22333973      PMCID: PMC3293632          DOI: 10.1038/msb.2012.2

Source DB:  PubMed          Journal:  Mol Syst Biol        ISSN: 1744-4292            Impact factor:   11.429


× No keyword cloud information.
microRNAs (miRNAs) are small, non-coding RNAs that regulate the expression of proteins through specific target sites in the corresponding transcripts. These small RNAs may function as oncogenes or tumor suppressors by modulating the levels of critical proteins, and their relevance in human disease and therapy is now under intense investigation. The human genome encodes about 1500 miRNAs that are thought to regulate more than 30% of protein-coding genes. Individual miRNAs can target multiple genes and each protein-coding gene can be regulated by several miRNAs, making the analysis of these networks difficult to explore. In a recent article published in Molecular Systems Biology, Uhlmann et al (2012) report a combined strategy to analyze the multiple miRNA–protein interactions that regulate cell proliferation in response to epidermal growth factor receptor (EGFR), an oncogenic pathway highly relevant in breast cancer. This analysis provides an unprecedented view of the combinatorial effort of miRNAs to control a signaling pathway at different levels. As oncogenic pathways are often resistant to the inhibition of individual regulators, this analysis also provides the molecular basis for selecting individual miRNAs, or a set of a few miRNAs, whose combined activity may be strong enough to treat breast tumors. Activation of the EGFR drives a signaling network that can lead to cell proliferation, survival, angiogenesis, invasion and metastasis. Aberrant expression or activity of EGFR has been strongly linked to the etiology of several human epithelial cancers, including lung, colorectal and breast cancer, among others (Wheeler et al, 2010). Not surprisingly, the EGFR pathway is probably the most explored next-generation target for breast cancer therapy, and several downstream signal transducers, such as RAS, AKT or CDKs, are also currently considered as cancer targets (Weickhardt et al, 2010; Wheeler et al, 2010). The EGFR pathway controls the expression of several miRNAs (Avraham et al, 2010; Garofalo et al, 2011), and some transcription factors and cell cycle regulators downstream of EGFR are known to be regulated by miRNAs at different levels (Avraham et al, 2010; Bueno and Malumbres, 2011). However, current information is scarce and typically describes single interactions between a miRNA and a relevant target transcript. Uhlmann et al (2012) used a genome-wide library of miRNA mimics to test their effect on the expression of 26 proteins in the EGFR-driven cell cycle pathway using reverse-phase protein arrays. Their findings validated some of the miRNA–protein interactions already known, such as the control of KRAS by miR-143 or the regulation of EGFR by miR-7 (Chen et al, 2009; Webster et al, 2009). In addition, other phenotypic interactions were found between 241 miRNAs and 25 EGFR network transcripts, revealing a total of 355 edges connecting them (Uhlmann et al, 2012). The high density of connections led the authors to investigate possible associations among the identified interactions. Using a novel framework for complex network analysis, they found that proteins controlling the EGFR-driven G1/S transition are frequently co-regulated by several miRNAs (Figure 1). For instance, independent expression of 19 miRNAs led to the concomitant downregulation of the cyclin-dependent kinase (CDK) 4 and upregulation of p27Kip1, a known CDK inhibitor, and both events likely contributed to cell cycle inhibition by these miRNAs (Uhlmann et al, 2012). The fact that the retinoblastoma protein was also concomitantly downregulated may seem surprising given the antiproliferative function of this molecule. The use of reporter assays on specific 3′-UTRs indicated that these changes were indirect and associated with direct co-repression of several EGFR core proteins. Thus, miR-124 was able to directly downregulate AKT2, p38MAPK and STAT3, probably resulting in the observed changes in cell cycle regulators (Figure 1). miR-124, miR-147 and miR-193a-3p showed the highest score in the network analysis, and their expression has a significant effect in the EGFR pathway by simultaneously targeting several of its components in several different cell lines (Uhlmann et al, 2012). As the expression of these miRNAs ultimately results in cell cycle inhibition, these three miRNAs may be relevant tumor suppressors by co-targeting several EGFR network proteins.
Figure 1

Control of the EGFR pathway and cell cycle entry by miRNAs. The EGF receptor uses several downstream pathways to drive cell cycle progression. Similarly, miRNAs simultaneously modulate several of these downstream pathways to effect cell cycle progression. For instance, miR-124 co-downregulates AKT2, p38MAPK and STAT3 to inhibit the EGFR pathway leading to CDK downregulation, p27Kip1 upregulation and cell cycle inhibition. miR-147 also participates in AKT2 downregulation and simultaneously represses Cyclins (Cyc). These two examples show how a single miRNA can target several components of a signaling pathway and how two miRNAs can co-regulate the same target. These data also suggest the therapeutic value of miR-124 and miR-147 in treating EGFR-dependent tumors. Only a few representative molecules are shown for clarity.

The fact that individual miRNAs may target several components of a single signaling pathway seems reasonably obvious. However, clear examples of this type of multi-level regulation are rare in the literature, probably due to current technical challenges, including difficulties in detecting miRNA–protein interactions with moderate effects. The study by Uhlmann et al (2012) now provides an experimental framework to detect multiple interactions in a single pathway that may be extended to a higher number of proteins or to other pathways. The analysis of endogenous miRNAs, rather than overexpressing exogenous sequences, and the separation of direct from indirect interactions remain as major challenges in these massive studies. A further level of complexity that needs to be clarified is how the combinational effect of several miRNAs can regulate the levels of a single protein. Although both miR-124 and miR-147 target AKT2 (Uhlmann et al, 2012; Figure 1), the relevance of this co-regulation deserves further analysis. Is it additive or simply redundant? Furthermore, the p27Kip1 family member p21Cip1 may be regulated by 28 miRNAs (Wu et al, 2010), and MYC, a major oncogene in several pathologies, can be targeted by nearly a dozen miRNAs with additive effects (Bueno et al, 2011). The fact that miRNA-target sites in many proteins are not evolutionarily conserved (Bueno et al, 2011; Uhlmann et al, 2012) suggests that the combinatorial effect of several miRNAs, rather than a single miRNA, may be the critical factor for modulating the levels of specific oncogenes. In general, it seems that individual miRNAs affect the expression of many proteins, even in the same pathway (Uhlmann et al, 2012), but in a rather mild manner. In addition, one gene can be regulated by several miRNAs (Wu et al, 2010; Bueno et al, 2011). Researchers need to use new technical approaches, such as the one reported by Uhlmann et al (2012), to characterize multiplicity, redundancy and the additive effect of miRNAs in these complex networks. These studies could identify miRNAs that may be efficient in the inhibition of a key pathway or even in the simultaneous inhibition of several pathways regulating cell survival and proliferation. The fact that AKT1 and ERK2, two major kinases in the PI3K and RAS oncogenic pathways, may be co-downregulated by 30 miRNAs (Uhlmann et al, 2012) is certainly a promising starting point that highlights the therapeutic potential of this approach. miRNAs seem to function like short, additive or redundant tweets with multiple targets, and it is now obvious that ‘social' networking is essential for the effect of these sequences in cell signaling. We now need to identify the relevant networks and validate their social utility.
  10 in total

Review 1.  Understanding resistance to EGFR inhibitors-impact on future treatment strategies.

Authors:  Deric L Wheeler; Emily F Dunn; Paul M Harari
Journal:  Nat Rev Clin Oncol       Date:  2010-06-15       Impact factor: 66.675

2.  Role of miR-143 targeting KRAS in colorectal tumorigenesis.

Authors:  X Chen; X Guo; H Zhang; Y Xiang; J Chen; Y Yin; X Cai; K Wang; G Wang; Y Ba; L Zhu; J Wang; R Yang; Y Zhang; Z Ren; K Zen; J Zhang; C-Y Zhang
Journal:  Oncogene       Date:  2009-01-12       Impact factor: 9.867

Review 3.  MicroRNAs and the cell cycle.

Authors:  María José Bueno; Marcos Malumbres
Journal:  Biochim Biophys Acta       Date:  2011-02-18

4.  Multiple microRNAs modulate p21Cip1/Waf1 expression by directly targeting its 3' untranslated region.

Authors:  S Wu; S Huang; J Ding; Y Zhao; L Liang; T Liu; R Zhan; X He
Journal:  Oncogene       Date:  2010-03-01       Impact factor: 9.867

5.  EGF decreases the abundance of microRNAs that restrain oncogenic transcription factors.

Authors:  Roi Avraham; Aldema Sas-Chen; Ohad Manor; Israel Steinfeld; Reut Shalgi; Gabi Tarcic; Noa Bossel; Amit Zeisel; Ido Amit; Yaara Zwang; Espen Enerly; Hege G Russnes; Francesca Biagioni; Marcella Mottolese; Sabrina Strano; Giovanni Blandino; Anne-Lise Børresen-Dale; Yitzhak Pilpel; Zohar Yakhini; Eran Segal; Yosef Yarden
Journal:  Sci Signal       Date:  2010-06-01       Impact factor: 8.192

6.  Combinatorial effects of microRNAs to suppress the Myc oncogenic pathway.

Authors:  María J Bueno; Marta Gómez de Cedrón; Gonzalo Gómez-López; Ignacio Pérez de Castro; Lorena Di Lisio; Santiago Montes-Moreno; Nerea Martínez; Manuel Guerrero; Ruth Sánchez-Martínez; Javier Santos; David G Pisano; Miguel Angel Piris; José Fernández-Piqueras; Marcos Malumbres
Journal:  Blood       Date:  2011-04-08       Impact factor: 22.113

Review 7.  Strategies for overcoming inherent and acquired resistance to EGFR inhibitors by targeting downstream effectors in the RAS/PI3K pathway.

Authors:  Andrew J Weickhardt; Niall C Tebbutt; John M Mariadason
Journal:  Curr Cancer Drug Targets       Date:  2010-12       Impact factor: 3.428

8.  Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7.

Authors:  Rebecca J Webster; Keith M Giles; Karina J Price; Priscilla M Zhang; John S Mattick; Peter J Leedman
Journal:  J Biol Chem       Date:  2008-12-10       Impact factor: 5.157

9.  EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers.

Authors:  Michela Garofalo; Giulia Romano; Gianpiero Di Leva; Gerard Nuovo; Young-Jun Jeon; Apollinaire Ngankeu; Jin Sun; Francesca Lovat; Hansjuerg Alder; Gerolama Condorelli; Jeffrey A Engelman; Mayumi Ono; Jin Kyung Rho; Luciano Cascione; Stefano Volinia; Kenneth P Nephew; Carlo M Croce
Journal:  Nat Med       Date:  2011-12-11       Impact factor: 87.241

10.  Global microRNA level regulation of EGFR-driven cell-cycle protein network in breast cancer.

Authors:  Stefan Uhlmann; Heiko Mannsperger; Jitao David Zhang; Emöke-Ágnes Horvat; Christian Schmidt; Moritz Küblbeck; Frauke Henjes; Aoife Ward; Ulrich Tschulena; Katharina Zweig; Ulrike Korf; Stefan Wiemann; Ozgür Sahin
Journal:  Mol Syst Biol       Date:  2012-02-14       Impact factor: 11.429

  10 in total
  13 in total

1.  Identification and characterization of microRNAs in pearl oyster Pinctada martensii by Solexa deep sequencing.

Authors:  Yu Jiao; Zhe Zheng; Xiaodong Du; Qingheng Wang; Ronglian Huang; Yuewen Deng; Shangli Shi; Xiaoxia Zhao
Journal:  Mar Biotechnol (NY)       Date:  2013-07-24       Impact factor: 3.619

Review 2.  MicroRNAs as biomarkers of cervical cancer development: a literature review on miR-125b and miR-34a.

Authors:  Joana Ribeiro; Hugo Sousa
Journal:  Mol Biol Rep       Date:  2014-01-09       Impact factor: 2.316

3.  Defining miRNA targets: balancing simplicity with complexity.

Authors:  Jane E Freedman; Kahraman Tanriverdi
Journal:  Circulation       Date:  2013-04-26       Impact factor: 29.690

4.  Synergistic anti-tumor effect of paclitaxel and miR-34a combined with ultrasound microbubbles on cervical cancer in vivo and in vitro.

Authors:  J Yu; Y Zhao; C Liu; B Hu; M Zhao; Y Ma; J Jiang
Journal:  Clin Transl Oncol       Date:  2019-05-15       Impact factor: 3.405

5.  Metformin resistant MDA-MB-468 cells exhibit EMT-like phenotype and increased migration capacity.

Authors:  Sahika Cingir Koker; Banu Yalcin; Irem Dogan Turacli
Journal:  Mol Biol Rep       Date:  2022-03-30       Impact factor: 2.742

6.  MicroRNA 16 modulates epithelial sodium channel in human alveolar epithelial cells.

Authors:  Prasanna Tamarapu Parthasarathy; Lakshmi Galam; Bao Huynh; Asfiya Yunus; Toaa Abuelenen; Annie Castillo; Gurukumar Kollongod Ramanathan; Ruan Cox; Narasaiah Kolliputi
Journal:  Biochem Biophys Res Commun       Date:  2012-08-23       Impact factor: 3.575

7.  miR-34a and miR-125b Expression in HPV Infection and Cervical Cancer Development.

Authors:  Joana Ribeiro; Joana Marinho-Dias; Paula Monteiro; Joana Loureiro; Inês Baldaque; Rui Medeiros; Hugo Sousa
Journal:  Biomed Res Int       Date:  2015-06-09       Impact factor: 3.411

8.  MicroRNA, Pm-miR-2305, Participates in Nacre Formation by Targeting Pearlin in Pearl Oyster Pinctada martensii.

Authors:  Yu Jiao; Zhe Zheng; Rongrong Tian; Xiaodong Du; Qingheng Wang; Ronglian Huang
Journal:  Int J Mol Sci       Date:  2015-09-07       Impact factor: 5.923

9.  Integrating sequence, expression and interaction data to determine condition-specific miRNA regulation.

Authors:  Hai-Son Le; Ziv Bar-Joseph
Journal:  Bioinformatics       Date:  2013-07-01       Impact factor: 6.937

10.  Assessing Low-Intensity Relationships in Complex Networks.

Authors:  Andreas Spitz; Anna Gimmler; Thorsten Stoeck; Katharina Anna Zweig; Emőke-Ágnes Horvát
Journal:  PLoS One       Date:  2016-04-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.